12:00 AM
 | 
Aug 14, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

BioSante, Medi-Ject preclinical data

The companies said that a DNA vaccine encoding viral proteins formulated with BTPH's CAP technology and delivered intramuscularly with...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >